Connect with us
  • Elysium

Dementia news

Breakthrough in understanding frontotemporal dementia

Study hailed as ‘transforming our understanding of the molecular basis’ of the neurodegenerative disease



Dr Benjamin Ryskeldi-Falcon, who led the study at the Medical Research Council Laboratory of Molecular Biology

A new protein linked to frontotemporal dementia has been identified, which could help establish a first potential therapeutic target for the condition. 

Most neurodegenerative diseases, including dementias, involve proteins aggregating into filaments called amyloids. In most of these diseases, researchers have identified the proteins that aggregate, allowing them to target these proteins for diagnostic tests and treatments.

But, in around ten per cent of cases of frontotemporal dementia, scientists had yet to identify the rogue protein – but now, the aggregated structures of the protein TAF15 have been pinpointed in these cases.

Frontotemporal dementia results from the degeneration of the frontal and temporal lobes of the brain, which control emotions, personality and behaviour, as well speech and understanding of words. It tends to start at a younger age than Alzheimer’s disease, often being diagnosed in people aged 45 to 65, although it can also affect younger or older people.

The work, led by scientists from the Medical Research Council (MRC) Laboratory of Molecular Biology, in Cambridge, has identified aggregated structures of a protein that could provide a target for the future development of diagnostic tests and treatments.

Dr Benjamin Ryskeldi-Falcon, who led the study, said: “This discovery transforms our understanding of the molecular basis of frontotemporal dementia. 

“It is a rare finding of a new member of the small group of proteins known to aggregate in neurodegenerative disease.

“Now that we have identified the key protein and its structure, we can start to target it for the diagnosis and therapy of this type of frontotemporal dementia, similar to strategies already in the pipeline for targeting the aggregates of amyloid-beta and tau proteins that characterise Alzheimer’s disease.”

The scientists used cutting-edge cryo-electron microscopy (cryo-EM) to study protein aggregates from the brains of four people who had this type of frontotemporal dementia at atomic resolution. 

In this type of dementia, scientists had long thought that a protein called FUS aggregated, based on similarities with other neurodegenerative diseases.

Using cryo-EM, the researchers were able to identify that the protein aggregates from each brain had the same atomic structure. Surprisingly, the protein was not FUS – it was another protein called TAF15.

Dr Stephan Tetter, first author on the paper, said: “This is an unexpected result because, before this study, TAF15 was not known to form amyloid filaments in neurodegenerative diseases and no structures of the protein existed. 

“Cryo-EM is transforming our understanding of the molecular pathology of dementia and neurodegenerative diseases more broadly by giving us insights that were beyond the capabilities of previous technologies.”

Dr Ryskeldi-Falcon added: “The technical challenge of performing cryo-EM meant that we were only able to look at the brains of four individuals. 

“However, now that we know the key protein and its structure, we have the potential to develop tools to screen for these abnormal protein aggregates in hundreds of patient samples to test how widespread they are.”

Some people who have frontotemporal dementia also have motor neuron disease, a condition in which individuals progressively lose control over their muscles. 

In this study, two of the individuals who donated their brains had signs of both diseases. For these individuals, the researchers identified the same aggregated structure of TAF15 in brain regions associated with motor neuron disease.

Dr Ryskeldi-Falcon said: “The presence of the same TAF15 aggregates in two individuals who had frontotemporal dementia and signs of motor neuron disease raises the possibility that TAF15 may contribute to both diseases. 

“We are now studying whether aberrant aggregated TAF15 is present in people who have motor neurone disease in the absence of frontotemporal dementia.”

This study was funded by the Medical Research Council, Alzheimer’s Research UK, the US National Institutes of Health, the Alzheimer’s Society, the Association for Frontotemporal Degeneration, the Swiss National Science Foundation, and the Leverhulme Trust.